Bio-Rad (BIO) Form 4: 914 RSUs Vest and 33-Share Sale Reported

Rhea-AI Filing Summary

Allison Schwartz, a director of Bio-Rad Laboratories (BIO), reported transactions on Form 4 reflecting the vesting of restricted stock units and a small sale of common stock. On 09/05/2025 she received 914 restricted stock units that vested, each convertible into one share, increasing her derivative-based holdings to 914 units. On 09/06/2025 an additional 92 shares were recorded as acquired on vesting and 33 shares were sold at a price of $295.43 each. After the reported transactions her direct beneficial ownership in Class A common stock is shown as 1,489 shares on 09/06/2025 and 1,456 shares following the sale. The filing documents the standard four-year vesting schedule for the RSUs at 25% per year.

Positive

• 914 restricted stock units vested on 09/05/2025, reflecting scheduled compensation delivery
• Reporting is complete and compliant with Section 16 requirements, including signature and dates

Negative

• Sale of 33 shares occurred on 09/06/2025 at $295.43 per share, reducing direct holdings from 1,489 to 1,456 shares

Insights

Corporate Governance Expert

TL;DR: Routine director RSU vesting and a small sale recorded; no governance red flags in the filing itself.

The Form 4 shows time-based restricted stock units vesting under a standard schedule and a modest disposition of 33 shares at $295.43. The transactions are consistent with compensation vesting and subsequent share processing. The disclosure is complete for Section 16 purposes and contains the required signature and transaction dates. There are no indications of unusual transfer mechanisms or related-party transfers in the filing.

Securities Analyst

TL;DR: Small-scale insider activity: 1,006 RSUs/shares reported acquired across two dates and a sale of 33 shares.

The report quantifies the change in beneficial ownership: 914 restricted stock units vested on 09/05/2025 and 92 units on 09/06/2025, with the filing showing 1,489 direct shares after the 09/06 acquisitions and 1,456 after the 33-share sale at $295.43. This is a routine disclosure of compensation-related vesting and a minor disposition; it does not present material information about company performance or strategy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allison Schwartz

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	09/06/2025		M		92(1)	A	$0	1,489	D
Bio-Rad A Common Stock	09/06/2025		F		33	D	$295.43	1,456	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	09/05/2025		A		914		(3)	(3)	Bio-Rad A Common Stock	914	$0	914	D
Restricted Stock Units	$0(2)	09/06/2025		M			92	(3)	(3)	Bio-Rad A Common Stock	92	$0	277	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Remarks:

	/s/ Allison Schwartz	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Allison Schwartz report on BIO Form 4?

The Form 4 reports the vesting of 914 restricted stock units on 09/05/2025, acquisition of 92 shares on 09/06/2025, and a sale of 33 shares at $295.43 each on 09/06/2025.

How many Bio-Rad Class A shares does Allison Schwartz beneficially own after these transactions?

The filing shows 1,489 shares following the 09/06 acquisitions and 1,456 shares after the 33-share sale.

What is the vesting schedule for the reported restricted stock units?

The restricted stock units vest over four years at 25% per year on each anniversary of the grant, as stated in the filing.

Do the reported transactions indicate any unusual transfer or related-party activity?

No. The filing shows standard vesting and a small sale; there are no disclosures of special transfer mechanisms or related-party transfers in the Form 4.

What was the price per share for the sale reported on the Form 4?

The sale of 33 shares on 09/06/2025 was reported at a price of $295.43 per share.